newsfilter
← Latest News
GlobeNewswire·

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with